Navigation Links
Genedata Announces New Solution for Efficient Analysis of High-Throughput Automated Patch Clamp Experiments

Genedata, a leading provider of advanced software solutions for R&D, today announced the general availability of a new solution for the automated analysis of Automated Patch Clamp (APC) data. The innovative software package has been developed in close collaboration with AstraZeneca and is available as part of Genedata Screener for Ion Channel Screening. New functionality added to the existing Screener APC package provides further in-depth characterization of compound effects on key ion channels, which are important for regulating cardiac action potential. AstraZeneca scientists will discuss the new analysis solution in a webinar - “A New Analysis Capability to Improve Assessment of Cardiac Liability in High Throughput Electrophysiology” (June 7, 2017).

Early indications of potential safety issues early in the R&D process minimize the risk of product liabilities and patient health issues. Modern APC technology provides scalable functional measurements of ion channels and, if analyzed properly, quickly yields qualitative data on large numbers of compounds. “We collaborated with Genedata to develop an integrated, high-throughput APC analysis solution. This is key to characterizing and ranking compounds alongside other key data as part of the drug discovery process,” noted Matt Bridgland-Taylor, associate principal scientist at AstraZeneca’s Innovative Medicines & Early Discovery Biotech Unit.

The high-throughput APC assays developed by AstraZeneca and supported by Genedata Screener are fundamental in eliminating key liabilities and designing strong leads in the drug discovery process. The solution increases specificity and throughput, which ultimately saves time, reduces risk, and improves R&D productivity.

Full APC Data Analysis with Genedata Screener
AstraZeneca uses the Nanion SyncroPatch 384PE system to obtain physiological ion channel data. Nanion is a partner in the Genedata Ready-to-Run program and closely works with Genedata to serve joint customers with a smooth integration of its hardware with Genedata Screener and optimized data analysis workflows for APC.

To optimize analysis of the Nanion SyncroPatch 384PE instrument’s high volume of complex current traces, new methods for automated data QC and quantifying the onset of effect to identify slow onset compounds were added to Genedata Screener. The resulting solution reads raw binary data directly from the instrument into Genedata Screener and enables:

  • Complete processing from raw data (sweeps) to cumulated compound results.
  • Systematic and early testing of compounds key cardiac channels (e.g. hERG potassium channel) in cumulative curve format.
  • Kinetic determination of the onset of effect as a parameter and the automatic identification of slow onset blockers previously undetected.
  • Automated analysis, annotation, and reporting of APC results on the same software platform used for all other screens at AstraZeneca.

Genedata Screener for Ion Channel Screening is a generic solution that works with a broad range of APC instruments. It incorporates cutting-edge capabilities such as: analysis of titration data in multiple scenarios; sweep normalization for cumulative curves; filtering and masking; current/voltage trace visualization; and robust quality metrics.

“The new developments have enhanced our ability to analyze and interrogate complex datasets for hERG and other key ion channels involved in the regulation of cardiac action potential, and substantially increases our throughput,” said Ana Teixeira, informatics analyst with AstraZeneca R&D who was responsible for the co-development project.

“Our collaboration with AstraZeneca exemplifies our efforts to deliver solutions that improve research productivity and efficiency,” noted Dr. Othmar Pfannes, CEO of Genedata. “With this latest addition to Genedata Screener, we enable our customers to systematically run affordable safety screens early in the lead discovery stage. The solution uses APC instruments to their full potential, and thus increases productivity and creates new efficiencies for pharmaceutical R&D.”

Editorial Note: AstraZeneca Webinar
Title: A New Analysis Capability to Improve Assessment of Cardiac Liability in High Throughput Electrophysiology
Date: June 7, 2017
Time: 9:00 am EDT

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
Follow Genedata on LinkedIn

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Expressionist 11.0 Released at ASMS 2017
2. Genedata Celebrates 20 Years of Bioinformatics Innovations at Bio-IT World
3. Leading Pharma and Research Organizations to Attend Genedata Screener Global User Group Meetings
4. Genedata Expands Into United Kingdom
5. SLAS2017 - Genedata Announces BMG LABTECH, Creoptix and TTP Labtech as New Ready-to-Run Partners
6. New Genedata Screener® APC Functionality and Integration with Nanion SyncroPatch 384PE at SLAS2017
7. Genedata Launches Data Science Services for Precision Medicine
8. Genedata Partners with Crescendo Biologics on Next-generation Immuno-oncology and ADC Programs
9. F-star Selects Genedata Biologics for Immuno-Oncology Therapeutics Discovery
10. Genedata Expands Partnership with MorphoSys to Support New Antibody Libraries and Developability Assessment
11. Genedata Announces the Release of Genedata Bioprocess - New Workflow Platform for Biopharmaceutical Development
Post Your Comments:
(Date:11/20/2018)... , ... November 19, 2018 , ... ... to announce the release of the Chinese translation of Best Practices: Recommendations for ... is a practice-changing publication aimed at advancing the science of biobanking to meet ...
(Date:11/15/2018)... FRANCISCO (PRWEB) , ... November 14, 2018 , ... ... campaign, bringing the world’s first self-learning snore-reduction mask to the public. It is ... a poorer quality of sleep for themselves and their partner. The resulting daytime ...
(Date:11/13/2018)... ... November 13, 2018 , ... Aditya Humad, Managing ... last week that asserts it is still trending upward with growing valuations based ... analysis describes market consolidation, pricing pressure and increased competition as reasons often cited ...
(Date:11/9/2018)... ... November 08, 2018 , ... ... Valenzuela, PhD, co-Founder, Chief Executive Officer and President of Andes Biotechnologies, to its ... the world, Dr. Valenzuela brings to uBiome expertise on the genetic studies of ...
Breaking Biology Technology:
(Date:12/5/2018)... ... December 04, 2018 , ... ... expertise and existing IP in the development of innovative solutions for which high-speed ... into diverse systems from microfluidics to industrial machinery and instrumentation, allowing partner companies ...
(Date:11/29/2018)... PRUSSIA, Pa. (PRWEB) , ... November 29, 2018 ... ... equity investment in Semba Biosciences with the intention of acquiring full ownership. The ... Equity Participation Agreement was executed on November 14, 2018. “We are extremely pleased ...
(Date:11/27/2018)... ... November 26, 2018 , ... uBiome, the leader in microbial ... IBDwatch and Gastroenterology Fellow at the University of Louisville, to its Medical Advisory ... Dr. Wuerth will bring to uBiome knowledge and research on IBD. The appointment ...
Breaking Biology News(10 mins):